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ABSTRACT 
 
Background: No effective pharmacotherapies exist for the treatment of crack cocaine use 
disorders. Emerging data suggests that cannabinoids may play a role in reducing cocaine-
related craving symptoms. This study investigated the intentional use of cannabis to reduce 
crack use among people who use illicit drugs (PWUD). 
 
Methods: Data were drawn from three prospective cohorts of PWUD in Vancouver, Canada. 
Using data from participants reporting intentional cannabis use to control crack use, we used 
generalized linear mixed-effects modeling to estimate the independent effect of three pre-
defined intentional cannabis use periods (i.e., before, during and after first reported intentional 
use to reduce crack use) on frequency of crack use.  
 
Results: Between 2012 and 2015, 122 participants reported using cannabis to reduce crack 
use, contributing a total of 620 observations. In adjusted analyses, compared to before 
periods, after periods were associated with reduced frequency of crack use (Adjusted Odds 
Ratio [AOR] = 1.89, 95% Confidence Interval [CI]: 1.02–3.45), but not the intentional use 
periods (AOR= 0.85, 95% CI: 0.51–1.41). Frequency of cannabis use in after periods was 
higher than in before periods (AOR = 4.72, 95% CI: 2.47–8.99), and showed a tendency to 
lower frequency than in intentional cannabis use periods (AOR = 0.56, 95% CI: 0.32–1.01). 
 
Conclusions: A period of intentional cannabis use to reduce crack use was associated with 
decreased frequency of crack use in subsequent periods among PWUD. Further clinical 
research to assess the potential of cannabinoids for the treatment of crack use disorders is 
warranted. 
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1. Introduction 
According to recent estimates, there are between 14 and 21 million current users of cocaine 
worldwide, of whom approximately seven million have a cocaine use disorder (Degenhardt et 
al., 2014; United Nations Office on Drugs and Crime, 2014). A substantial proportion of 
cocaine use is thought to occur in the form of crack cocaine, particularly among marginalized 
populations in urban settings in North and South America (Fischer, Cruz, Bastos, & Tyndall, 
2013). Crack cocaine use, in turn, is associated with a number of health-, social-, and legal-
related harms (DeBeck, Kerr, et al., 2009; DeBeck, Small, et al., 2009; Degenhardt et al., 
2011; Fischer, Blanken, et al., 2015; Fischer & Coghlan, 2007; Fischer et al., 2013; Fischer, 
Powis, Firestone Cruz, Rudzinski, & Rehm, 2008; Shannon et al., 2008). Unfortunately, 
despite the substantial public health and social challenges posed by crack use, no effective 
pharmacotherapy exists for the treatment of crack cocaine use disorders, and the long-term 
effectiveness of available psychosocial interventions is limited (Fischer, Blanken, et al., 2015). 
Therefore, there is a critical need for continuous research on innovative therapeutic 
approaches for crack use disorders.  
A growing body of evidence has described the key role of the human endocannabinoid system 
(ECBS) in the neurobiological adaptations and behavioral processes underlying substance 
use disorders (Prud'homme, Cata, & Jutras-Aswad, 2015). While data from small 
observational studies and animal models suggest that some cannabinoids may be effective in 
reducing craving — one of the major predictors of crack cocaine use (Paliwal, Hyman, & Sinha, 
2008) — more robust data is currently lacking (Dreher, 2002; Fischer, Kuganesan, et al., 
2015). Thus, the objective of this study was to investigate the potential impact of the intentional 
  
use of cannabis to reduce crack use on the subsequent crack use frequency in a community-
recruited sample of people who use illicit drugs (PWUD) in Vancouver, Canada. 
 
2. Materials and methods 
2.1. Study design, procedures and population 
Data for this study were drawn from three open and ongoing prospective cohorts of PWUD 
with harmonized procedures for recruitment, follow-up and data collection, in Vancouver, 
Canada. These include the Vancouver Injection Drug Users Study (VIDUS); the AIDS Care 
Cohort to Evaluate exposure to Survival Services (ACCESS); and the At-Risk Youth Study 
(ARYS). VIDUS began recruitment in 1996, and ARYS and ACCESS in 2005. Individuals are 
recruited through snowball sampling and extensive street outreach in the city’s Downtown 
Eastside and Downtown South neighborhoods, both urban areas with high levels of illicit drug 
use, homelessness and marginalization. Where possible, all information gathering procedures 
are conducted in the same way regardless of a participant’s cohort membership to allow for 
analysis of merged data of studies focusing on outcomes and behaviors that cut across 
cohorts, as is the case of the present analysis. In brief, to be eligible, individuals need to reside 
within the greater Vancouver region and have used illicit drugs (other than cannabis) in the 
previous month. In addition, each cohort has specific inclusion criteria. VIDUS consists of HIV-
negative adults (≥ 18 years) who injected drugs in the month prior to enrolment, ACCESS of 
HIV-positive adults, and ARYS of street-involved youth (14-26 years old.) Recruitment and 
study procedures for the three studies have been described in detail previously (Strathdee et 
al., 1998; Wood et al., 2008; Wood, Stoltz, Montaner, & Kerr, 2006).  
  
After providing written informed consent, at baseline and semi-annually thereafter, participants 
completed an interviewer-administered questionnaire, provided blood for HIV/ HCV serological 
testing, and were examined by a study nurse who provides basic medical care and referrals 
to additional health services where appropriate. The questionnaire elicited data on socio-
demographic characteristics, drug use patterns, health care access and utilization, including 
HIV and addiction care, as well as other relevant exposures. Participants received a $30 
honorarium at each study visit. The VIDUS, ACCESS and ARYS studies have received ethical 
approval by the University of British Columbia/Providence Health Care Research Ethics 
Board. 
For the present study, data from the three cohorts were combined to achieve sufficient power 
to examine the potential impact of intentional cannabis use on frequency of crack use. The 
analytic sample was restricted to participants who reported intentional use of cannabis to 
reduce their use of crack at least once during the study period. Specifically, individuals were 
included if they answered yes to the question "In the last 6 months, did you substitute one 
drug for another in order to control or slow down your use”, and indicated that they were using 
cannabis to reduce their use of crack. As this question was added to the questionnaires in 
June 2012, we considered all observations collected between this date and May 2015. Of 
note, measurements of crack cocaine use were longitudinal and fully distinct and independent 
from measurements of cannabis use, and the “substitution” question was systematically asked 
after these assessments.  
2.2. Measures 
The primary outcome of interest was the self-reported frequency of crack use in the six-month 
period prior to each study interview. At each semi-annual follow-up interview, participants were 
  
asked to estimate their crack use since the last visit, using six predefined frequency categories: 
(1) ≥ daily, (2) 2-3 times a week, (3) about once a week, (4) 1-3 times a month, (5) less than 
once a month, and (6) no use. We defined a reduction in use as a change from one frequency 
category to any other lower frequency category. 
The primary explanatory variable was the cannabis use period. Three periods were defined: 
(1) before, observations before the first report of intentional cannabis use to reduce crack use, 
(2) during, interview-periods where the participant reported using cannabis to control the use 
of crack, and (3) after, observations after the first report of intentional cannabis use where no 
intentional use was reported. 
We also considered a set of socio-demographic variables that were hypothesized to potentially 
confound the relationship between intentional cannabis use and crack use. Time-fixed 
variables of interest at baseline included: gender (male versus non-male); ancestry 
(Caucasian versus non-Caucasian); highest educational attainment (high school or 
postsecondary education vs. less than high school completion). Time-varying variables 
(updated at each semi-annual follow-up) included age (per year older), place of residency 
(Downtown Eastside, one of the largest open drug scenes in North America, versus other 
neighborhoods), and seeking treatment for crack cocaine. 
2.3. Statistical analyses 
As a first step, we compared characteristics of participants stratified by daily crack cocaine 
use in the last 6 months prior to their first interview in the study period (e.g., June 2012). We 
used the Pearson’s chi-squared (or Fisher’s exact test in the presence of small cell counts) 
for categorical variables, and the Wilcoxon rank sum test for continuous variables. Next, we 
  
examined the frequency of crack and cannabis use in each of the three cannabis use periods. 
Then, we estimated the bivariable relationship between the primary explanatory variable (i.e., 
cannabis use period, using the before period as the reference category) and each secondary 
covariate on frequency of crack use. We used generalized linear mixed-effects models 
(GLMM), treating the frequency of crack use as an ordinal outcome, and incorporating random 
intercepts to account for repeated measurements from the same participants over time. The 
proportional odds assumption was checked using the score test. This approach (i.e., ordinal 
outcome, random intercept) also allows for an estimation of the odds of changes in the 
frequency of crack cocaine use, regardless of the frequency each participant started with. As 
we modeled lower frequency of crack use, Odds Ratio (OR) >1 means decreased frequency 
of use compared to the “before” period, while OR <1 means increased frequency of use. To 
assess the independent effect of the cannabis use period on reduced crack cocaine use, we 
then fit a fixed multivariable model with the main explanatory variable and all secondary 
covariates that were associated with the outcome in bivariable analysis at a p-value <0.10. In 
addition, we forced into the multivariable model a variable representing calendar year of the 
interview to control for the cohort effect, and a variable representing cohort designation to 
control for possible heterogeneity of effect across cohorts. 
Finally, to explore changes in cannabis use coinciding with the three cannabis use periods, 
we built an analogous 6-level cannabis use frequency variable and followed a similar approach 
as described above. The only difference is that for cannabis use, we modeled higher frequency 
of use instead of reduced frequency (i.e., OR>1 = higher frequency of cannabis use, and OR<1 
= lower frequency). All statistical analyses were performed using the SAS software version 9.4 
(SAS, Cary, NC), and two-sided p-values <0.05 were considered statistically significant. 
  
 
3. Results 
Between June 2012 and May 2015, 837 VIDUS, 670 ACCESS, and 493 ARYS participants 
completed at least one follow-up interview. Of these, 122 participants (49 VIDUS, 51 ACCESS, 
and 22 ARYS participants) reported intentional use of cannabis to reduce crack use at least 
once and were thus included in the present analysis, contributing to a total of 620 observations. 
The median duration of follow-up per participant during the study period was 29.1 (Inter-
Quartile Range [IQR]: 24.0–30.1) months, resulting in a total of 268.1 person-years of follow 
up. Baseline characteristics of study participants stratified by ≥daily crack use in the last six 
months are shown in Table 1. The median age was 46 years (IQR: 34–53), 89 (73.0%) were 
male, and 51 (41.8%) HIV-positive. The majority of participants reported intentional use of 
cannabis to control crack only once (88, 72.1%), 26 (21.3%) reported intentional use of 
cannabis in two periods, and 8 (6.6%), 3 times or more.  
Table 1. Baseline characteristics of 122 illicit drug users who ever intentionally used 
cannabis to reduce crack cocaine use, stratified by daily crack cocaine use in the last 
six months 
 
Characteristic 
Total (%) 
(n = 122) 
≥ Daily crack cocaine use 
p - value Yes (%) 
(n = 45) 
No (%) 
(n = 77) 
Socio-demographic 
characteristics 
    
Age (med, IQR) 46 (34-53) 45 (34-54) 47 (35-52) 0.853£ 
Male gender 89 (73.0) 29 (64.4) 60 (77.9) 0.106 
Caucasian ethnicity 61 (50.0) 21 (46.7) 40 (52.0) 0.574 
High school education or 
higher* 
59 (48.4) 23 (51.1) 36 (46.8) 0.691 
Residency in the Downtown 
Eastside* 
68 (55.7) 27 (60.0) 41 (53.3) 0.469 
  
Seek treatment for crack* 22 (18.0) 11 (24.4) 11 (14.3) 0.159 
Frequency of cannabis use*     
Did not use 17 (13.9) 5 (11.1) 12 (15.6) 0.837€ 
Less than once a month 6 (4.9) 1 (2.2) 5 (6.5)  
1-3 times a month 8 (6.6) 3 (6.7) 5 (6.5)  
About once a week 10 (8.2) 5 (11.1) 5 (6.5)  
2-3 times a week 23 (18.9) 9 (20.0) 14 (18.2)  
≥ Daily 58 (47.5) 22 (48.9) 36 (46.7)  
* Refers to the 6-month period prior to the interview 
£ Wilcoxon rank sum test 
€ Fisher’s exact test  
 
Figure 1 presents the frequencies of crack cocaine (panel A) and cannabis use (Panel B) in 
each of the three cannabis use periods (i.e., before, during, after). As shown in this figure, “2-
3 times a week” and “≥daily” frequencies categories of crack use experienced the largest 
reductions between the before and after period. 
Figure 1. Frequencies of crack cocaine (Panel A) and cannabis use (Panel B) in each of 
the cannabis use periods.  
 
 
  
As indicated in Table 2, in unadjusted analysis, compared to the before period, the odds of 
reduced frequency of crack use was higher in the after period (Odds Ratio [OR] = 3.93, 95% 
Confidence interval [CI] 2.57–5.99) but not during intentional cannabis use periods (OR = 1.14, 
95% CI 0.73–1.77). In a multivariable GLMM, the after period remained positively associated 
with lower frequency of crack use (Adjusted Odds Ratio [AOR] = 1.89, 95%CI: 1.01–3.45). 
Table 2. Bivariable and multivariable generalized linear mixed-effects analyses of 
reduced frequency of crack cocaine use among 122 illicit drug users reporting 
intentional use of cannabis to reduce crack use, Vancouver, Canada (2012-2015) 
 
Variable  
Odds Ratio 
(95% CI) 
p-value 
Adjusted Odds 
Ratio (95% CI) ‡€ 
p-value 
Primary variable of 
interest 
  
  
Cannabis use period*     
Before 1.00  1.00  
During  1.14 (0.73 – 1.77) 0.579 0.85 (0.51 – 1.41) 0.524 
After 3.93 (2.57 – 5.99) <0.001 1.89 (1.01 – 3.45) 0.043 
Covariates     
Age (per year older)£† 0.97 (0.95 – 1.00) 0.048 0.93 (0.89 – 0.97) 0.002 
Male gender† 2.58 (1.27 – 5.25) 0.009 3.63 (1.70 – 7.73) <0.001 
Caucasian ethnicity 1.35 (0.71 – 2.56) 0.359   
High school education or 
higher 
0.87 (0.46 – 1.65) 0.668 
  
Residency in the 
Downtown Eastside£† 
0.42 (0.26 – 0.69) <0.001 0.51 (0.31 – 0.85) 0.009 
Seek treatment for crack£† 0.31 (0.17 – 0.54) <0.001 0.34 (0.19 – 0.62) <0.001 
* Intentional use of cannabis to reduce crack use  
£ Refers to the 6-month period prior to the interview 
† p-value <0.10 in bivariable analysis and included in the multivariable model 
‡ Only the list of variables included in the multivariable model is presented in this column 
€ Estimates also adjusted for calendar year of the interview and cohort designation 
 
Table 3 presents the unadjusted and adjusted GLMM analyses of the relationship between 
the cannabis use period and frequency of cannabis use. In adjusted analyses, compared to 
the before period, both the intentional use (AOR = 4.72, 95% CI 2.47–8.99) and the after 
  
periods (AOR = 2.63, 95% CI 1.21 – 5.74) were associated with higher frequency of cannabis 
use. In addition, cannabis use in the after periods showed a tendency to lower frequency than 
during the intentional use period (AOR = 0.56, 95% CI: 0.32–1.01, p=0.052), data not shown). 
Table 3. Bivariable and multivariable generalized linear mixed-effects analyses of 
higher frequency of cannabis use among 122 illicit drug users reporting intentional use 
of cannabis to reduce crack use, Vancouver, Canada (2012-2015) 
 
Variable  
Odds Ratio 
(95% CI) 
p-
value 
Adjusted Odds 
Ratio (95% CI) ‡€ 
p-
value 
Primary variable of interest     
Cannabis use period*     
Before 1.00  1.00  
During  5.48 (3.10 – 9.68) <0.001 4.72 (2.47 – 8.99) <0.001 
After 2.66 (1.61 – 4.40) <0.001 2.63 (1.21 – 5.74) 0.015 
Covariates     
Age (per year older) £† 0.95 (0.91 – 0.99) 0.010 0.97 (0.91 – 1.04) 0.437 
Male gender 1.30 (0.45 – 3.73) 0.624   
Caucasian ethnicity 0.88 (0.35 – 2.24) 0.992   
High school education or 
higher 
1.11 (0.59 – 2.06) 0.753 
  
Residency in the Downtown 
Eastside£ 
1.69 (0.85 – 3.36) 0.132 
  
Seek treatment for crack£     
* Intentional use of cannabis to reduce crack use  
£ Refers to the 6-month period prior to the interview 
† p-value <0.10 in bivariable analysis and included in the multivariable model 
‡ Only the list of variables included in the multivariable model is presented in this column 
€ Estimates also adjusted for calendar year of the interview and cohort designation 
 
 
4. Discussion 
In this longitudinal study, we observed that a period of self-reported intentional use of cannabis 
to control crack use was associated with subsequent periods of reduced use of crack among 
  
a community-recruited sample of PWUD in Vancouver, Canada. Interestingly, it was only the 
period after such intentional use of cannabis that was positively associated with decreased 
frequency of crack use, while the frequency of crack use during periods of intentional cannabis 
use was not statistically different to the before period. Consistent with the substitution 
hypothesis (Lau et al., 2015), the frequency of cannabis use increased both during and after 
the first reported intentional use of cannabis to reduce crack use. However, while frequencies 
of cannabis use were higher in the after periods compared to baseline levels (i.e., before 
periods), they show a decreasing trend than during periods where cannabis use was reported 
as a means to reduce crack use.  
Our findings are in line with previous results from preliminary observational studies including 
a small case-series study from Brazil that followed 25 treatment-seeking individuals with crack 
use disorders who reported using cannabis to reduce cocaine-related craving symptoms. Over 
a nine-month follow-up period, the majority (68%) stopped using crack. Further, similar to our 
study, cannabis use peaked during the first three months of follow-up, with only occasional 
use of cannabis reported in the remainder six months of follow-up (Labigalini, Rodrigues, & 
Da Silveira, 1999). Qualitative studies among crack users in Jamaica and Brazil also indicate 
that cannabis is frequently used as a self-medication strategy to reduce craving and other 
undesirable effects of crack (e.g., feelings of paranoia and anxiety) which in turn results in 
decreased cocaine-seeking behaviour (and associated illicit or endangering activities to 
procure the drug) and use of crack (Dreher, 2002; Goncalves & Nappo, 2015). Conversely, 
other studies have revealed that long-term cannabis dependence might increase cocaine 
craving and risk of relapse among individuals with poly-drug substance use disorders 
(Aharonovich et al., 2005; Fox, Tuit, & Sinha, 2013; Viola et al., 2014), suggesting that patterns 
of cannabis use and dependence, and the timing of self-medication with cannabis might play 
  
a role in explaining the different outcomes across studies. In addition, qualitative research may 
help to better understand motivations and expectations of cannabis use among crack users. 
Emerging pre-clinical and clinical data provide biological plausibility for the findings of the 
present analysis. Specifically, Parker et al. demonstrated that both Δ9-tetrahydrocannabinol 
(THC) and cannabidiol (CBD), the two primary cannabinoids found in the cannabis plant, 
facilitated extinction of cocaine-induced conditioned place preference (CPP) in rat models, a 
suggested proxy for craving (Parker, Burton, Sorge, Yakiwchuk, & Mechoulam, 2004). CBD 
was also found to persistently disrupt the reconsolidation of cocaine- and opioid-related 
memory (de Carvalho & Takahashi, 2016), and to reduce cue-induced heroin-seeking 
behavior in rats, with effects lasting for at least two weeks after CBD administration (Ren, 
Whittard, Higuera-Matas, Morris, & Hurd, 2009). Based on this encouraging animal data, 
clinical trials exploring the potential role of CBD in addiction treatment have started to arise. 
Consistent with results from pre-clinical studies, findings from pilot human trials have indicated 
that single doses of 400 or 800 mg of CBD for three consecutive days were well tolerated and 
effective in decreasing cue-induced and general craving, as well as anxiety among heroin-
dependent individuals, with persistent effects of up to seven days (Hurd et al., 2015; Manini et 
al., 2015). Although no clinical studies have yet been conducted among individuals with 
cocaine use disorders, taken together, findings from this study and others (Dreher, 2002; 
Goncalves & Nappo, 2015; Hurd et al., 2015; Labigalini et al., 1999; Manini et al., 2015; Parker 
et al., 2004; Prud'homme et al., 2015; Ren et al., 2009) support calls to further investigate the 
therapeutic potential of cannabinoids to attenuate craving and other cocaine-cessation 
symptoms (e.g., anxiety), and thus lower rates of relapse (Fischer, Kuganesan, et al., 2015).  
  
Both temporality and a plausible biological pathway support a potential causal relationship 
between self-medication with cannabis and reduced crack use. However, findings from the 
present study should be interpreted in light of a number of limitations. First, the three parents 
cohorts from where our data were drawn are not random samples; therefore our results may 
not be generalizable to the larger population of drug users in Vancouver or other settings. That 
said, socio-demographic characteristics of our study sample are similar to epidemiological 
data of crack use across Canada, including socio-economic marginalization and high 
prevalence of HIV (Fischer & Coghlan, 2007; Fischer et al., 2013). Second, as we did not have 
access to a comparison group of individuals trying to reduce their use of crack through a 
different modality, we cannot exclude the possibility that the observed reductions were the 
product of a different exposure (e.g., cognitive strategies). Third, the use of observational data 
with non-random assignment to the exposure of interest further degrades our ability to assign 
causality. Fourth, drug use patterns assessed in this analysis relied on self-reported data, 
which might be subject to social-desirability bias and underreporting. However, previous 
research has shown PWUD’s reports of drug use to be reliable (De Irala, Bigelow, McCusker, 
Hindin, & Zheng, 1996; Langendam, van Haastrecht, & van Ameijden, 1999). Further, we have 
no reason to believe that the magnitude of this potential bias, if any, will differ among cannabis 
substitution periods. Fifth, our study instrument does not collect information on the specific 
composition of the cannabis used (e.g., concentrations of THC and CBD) or craving measures, 
and thus we are not able to attribute the observed effects to a specific cannabinoid or dosage, 
or mechanism of action. 
 
5. Conclusions 
  
In summary, we found that a period of intentional cannabis use to reduce use of crack was 
associated with subsequent reductions in the frequency of crack cocaine use among PWUD 
in Vancouver, Canada. Although more research is needed to confirm these results, findings 
from the present analysis are in line with previous observational and preclinical data 
suggesting that cannabinoids may play a role in attenuating cocaine-related craving 
symptoms, and thus reduce crack use or relapse. Given the substantial global burden of 
morbidity and mortality attributable to crack cocaine use disorders alongside a lack of effective 
pharmacotherapies, we echo calls for rigorous experimental research on cannabinoids as a 
potential treatment for crack cocaine use disorders (Fischer, Kuganesan, et al., 2015). 
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